MDXG MiMedx Group Inc.

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30

MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

The conference call can be accessed using the following information:

Webcast:

U.S. Investors: 877-407-6184

International Investors: 201-389-0877

Conference ID: 13745475

A replay of the webcast will be available for approximately 30 days on the Company’s website at following the conclusion of the event.

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit .

Contact:

Matt Notarianni

Investor Relations

470-304-7291



EN
16/04/2024

Underlying

MDXGMiMedx Group Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 21st Annual Institutional Investor Conference Wednesday, May 29, 2024Renaissance Minneapolis Hotel, The Depot225 3rd Avenue SouthMinneapolis, MN Northland Growth Conference 2024Tuesday, June 25, 2024Virtual Investors interested in meeting with senior management at these events may contact their respecti...

May 15, 2024 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces First Quarter 2024 Operating and Financial Results

MIMEDX Announces First Quarter 2024 Operating and Financial Results Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024, at 4:30 PM ET MARIETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2024. Recent Operating and Financial Highlights: First quarter 2024 net ...

April 30, 2024 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conf...

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30 MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Web...

April 16, 2024 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) fr...

MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits and 2024 Adjusted EBITDA1 Margin Above 20% MARIETTA, Ga., March 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has i...

March 27, 2024 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating wounds MARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity Biosciences that will enable the Company to add xenograft products to its portf...

March 20, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch